Treatment of infants with congenital toxoplasmosis: Tolerability and plasma concentrations of sulfadiazine and pyrimethamine

European Journal of Pediatrics

Volumn 165, Issue 1, 2006, Pages 19-25

  Schmidt, Dorte Remmer ^a   Hogh, Birthe ^b   Andersen, Ole ^c   Hansen, Steen Honoré ^d   Dalhoff, Kim ^b   Petersen, Eskild ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Congenital; Plasma concentrations; Tolerability; Toxoplasma gondii; Treatment

Indexed keywords

AZITHROMYCIN; FOLINIC ACID; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PARASITE ANTIBODY; PREDNISOLONE; PYRIMETHAMINE; SULFADIAZINE;

ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD SAMPLING; BODY WEIGHT; CHORIORETINITIS; CONCENTRATION (PARAMETERS); CONGENITAL TOXOPLASMOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; EYE INJURY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; INFANT; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NEUTROPENIA; NEUTROPHIL COUNT; PHENYLKETONURIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; WEIGHT GAIN;

ANTIPROTOZOAL AGENTS; DENMARK; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; INFANT; INFANT, NEWBORN; PYRIMETHAMINE; SULFADIAZINE; TOXOPLASMOSIS, CONGENITAL; TREATMENT OUTCOME;

EID: 29244460651     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-005-1665-4     Document Type: Article

References (28)

1. Astier H, Renard C, Cheminel V, Soares O, Mounier C, Peyron F, Chaulet JF (1997) Simultaneous determination of pyrimethamine and sulphadoxine in human plasma by high-performance liquid chromatography after automated liquid-solid extraction. J Chromatogr B Biomed Sci Appl 698:217-223
2. Bosch-Driessen EH, Rothova A (1998) Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J Ophthalmol 82:858-860
3. Corvaisier S, Charpiat B, Mounier C, Wallon M, Leboucher G, Kurdi MA, Chaulet JF, Peyron F (2004) Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother 48:3794-3800
4. Derouin F, G'rard L, Farinotti R, Maslo C, Leport C (1998) Determination of the inhibitory effect on Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis. J Acquir Immune Defic Syndr 19:50-54
5. Dunn D, Wallon M, Peyron F, Petersen E, Gilbert R (1999) Mother to child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 353:1829-1833
6. Frenkel JK, Hitchings GH (1957) Relative reversal by vitamins (p-aminobenzoic, folic and folinic acid) of the effects of sulfadiazine and pyrimethamine on Toxoplasma, mouse and man. Antibiot Chemother 7:630-638
7. Gilbert R, Dunn D, Wallon M, Hayde M, Prusa A, Lebech M, Kortbeek T, Peyron F, Pollak A, Petersen E (2001) Ecological comparison of the risk of mother to child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. Epidemiol Infect 127:113-120
8. Gilbert R, Gras L, and the European Multicentre Study on Congenital Toxoplasmosis (2003) Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 110:112-120
9. Gras L, Wallon M, Pollak A, et al for The European Multi-centre Study on Congenital Toxoplasmosis (2004) Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. BJOG (in press)
10. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, Pasternack MS, Hoff R, Eaton RB, Grady GF, New England Regional Toxoplasma Working Group (1994) Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 330:1858-1863
11. Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, Descombey D, Forestier F (1989) Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 115:765-769
12. Johannessen JK, Christiansen I, Schmidt DR, Petersen E, Hansen SH (2005) Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis. J Pharm Biomed Anal 36:1093-1098
13. Jordan MK, Burstein AH, Rock-Kress D, Alfaro RM, Pau AK, Kovacs JA, Piscitelli SC (2004) Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 48:635-637
14. Kaufman HE, Geisler PH (1960) The haematologic toxicity of pyrimethamine. Arch Ophthalmol 64:140-146
15. Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H (1986) Results of a 20-year follow-up of congenital toxoplasmosis. Lancet i:254-256
16. Lebech M, Andersen O, Christensen NC, Nielsen HE, Peitersen B, Rechnitzer C, Larsen SO, Nørgaard-Pedersen B, Petersen E, and the Danish Congenital Toxoplasmosis Study Group (1999) Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 353:1834-1837
17. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, Wolters C, Stein L, Stein M, Schey W, Remington J, Meier P, Johnson D, Heydeman P, Holfels E, Withers S, Mack D, Brown C, Patton D, McLeod R (1994) Early and longitudinal evaluation of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin Infect Dis 18:38-72
18. McLeod R, Mack D, Foss R, Boyer K, Withers S, Levin S, Hubbell J (1992) Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from children treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother 36:1040-1048
19. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363:1965-1976
20. Nathan DG, Orkin SH, Ginsburg D, Look TA (2003) Hematology of Infancy and Childhood, 6th edn. Saunders, New York
21. Ng SC, Gomez JM, Rajadurai VS, Saw SM, Quak SH (2003) Establishing enterai feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. J Pediatr Gastroenterol Nutr 37:554-558
22. Petersen E, Schmidt DR (2003) Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev Anti Infect Ther 1:175-182
23. Phillips-Howard PA, West LJ (1990) Serious adverse drugs reactions to pyrimethamine-sulfadoxine, pyrimethamine-dapsone and amodiaquine in Britain. J R Soc Med 83:82-85
24. Polito C, La Manna A, Mansi L, Rambaldi PF, Papale MR, Marte A, Di Toro R (1999) Body growth in early diagnosed vesicoureteric reflux. Pediatr Nephrol 13:876-879
25. Trenque T, Simon N, Villena I, Chemla C, Quereux C, Leroux B, Jaussaud R, Remy G, Dupouy D, Millart H, Pinon JM, Urien S (2004) Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol 57:735-741
26. Villena I, Aubert D, Leroux B, Dupouy D, Talmud M, Chemla C, Trenque T, Schmit G, Quereux C, Guenounou M, Pluot M, Bonhomme A, Pinon JM (1998) Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Scand J Infect Dis 30:295-300
27. Wallon M, Liou C, Garner P, Peyron F (1999) Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. BMJ 318:1511-1514
28. World Health Organization (1988) Report of the WHO consultation on public health aspects of toxoplasmosis. 6-8 October 1988, WHO/CDS/VPH88.74, Hanover, Germany